Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 5
2021 4
2022 8
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint A Jr, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A. Bhatt S, et al. Cancer Cell. 2020 Dec 14;38(6):872-890.e6. doi: 10.1016/j.ccell.2020.10.010. Epub 2020 Nov 19. Cancer Cell. 2020. PMID: 33217342 Free PMC article.
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.
Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C, Perlee S, Perner F, Rahnamoun H, Theall ACP, Henrich JA, Zhu Q, Nowak RP, Kim YJ, Parvin S, Cremer A, Olsen SN, Eleuteri NA, Pikman Y, McGeehan GM, Stegmaier K, Letai A, Fischer ES, Liu XS, Armstrong SA. Aubrey BJ, et al. Nat Cancer. 2022 May;3(5):595-613. doi: 10.1038/s43018-022-00366-1. Epub 2022 May 9. Nat Cancer. 2022. PMID: 35534777 Free PMC article.
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Zhang Q, et al. Signal Transduct Target Ther. 2022 Feb 21;7(1):51. doi: 10.1038/s41392-021-00870-3. Signal Transduct Target Ther. 2022. PMID: 35185150 Free PMC article.
Apoptosis: Directly Targeted at Last.
Letai A. Letai A. J Clin Oncol. 2022 May 20;40(15):1693-1695. doi: 10.1200/JCO.22.00304. Epub 2022 Mar 23. J Clin Oncol. 2022. PMID: 35319999 Free PMC article. No abstract available.
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, Trujillo-Alonso V, Teater MR, van Besien H, Gibbs-Curtis D, Ueno H, Parvin S, Letai A, Mathew S, Singh A, Cesarman E, Melnick A, Giulino-Roth L. Scholze H, et al. Blood Adv. 2020 Oct 27;4(20):5226-5231. doi: 10.1182/bloodadvances.2020002580. Blood Adv. 2020. PMID: 33104794 Free PMC article.
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
Hemming ML, Bhola P, Loycano MA, Anderson JA, Taddei ML, Doyle LA, Lavrova E, Andersen JL, Klega KS, Benson MR, Crompton BD, Raut CP, George S, Letai A, Demetri GD, Sicinska E. Hemming ML, et al. Clin Cancer Res. 2022 Jun 1;28(11):2397-2408. doi: 10.1158/1078-0432.CCR-21-3523. Clin Cancer Res. 2022. PMID: 35325095 Free PMC article.
19 results